PMID- 37655112
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230902
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Expression of p53 as a biomarker in determining response to apatinib for advanced 
      gastric cancer.
PG  - 1203980
LID - 10.3389/fonc.2023.1203980 [doi]
LID - 1203980
AB  - BACKGROUND: Apatinib has shown outstanding value in the treatment of advanced 
      gastric cancer (AGC). However, no biomarkers are available to select AGC patients 
      who will benefit from apatinib. The aim of the present study was to investigate 
      the association between p53 and Ki67 expression of and the outcome in AGC 
      patients treated with apatinib. METHODS: From December 2015 to December 2020, 92 
      AGC patients were enrolled and was retrospectively evaluated. They were given 
      apatinib at a daily dose of 500 or 250 mg every 4 weeks to monitor clinical 
      efficacy and adverse events (AEs). Kaplan-Meier method was used for survival 
      analysis. Expression of p53 and Ki67 was detected by immunohistochemistry (IHC) 
      and correlated with survival. RESULTS: Among 92 evaluable patients, the objective 
      response rate (ORR) and disease control rate (DCR) were 17.4% and 79.3%, 
      respectively, and none of them achieved a CR, 16 achieved a PR (17.4%) (95% CI 
      9.8%-26.1%). Stable disease (SD) was observed in 57.6% of patients (95% CI 
      49.2%-69.9%) and PD in 21.7% of patients (95% CI 13.6%-31.3%). The median 
      progression free survival (mPFS) was 122.7 +/- 8.2 days, and the median overall 
      survival (mOS) was 203.4 +/- 11.9 days. P53 expression was observed in 35 patients 
      (38.0%) and high expression of Ki67 was detected in 34 patients (37.0%). There 
      was a statistically significant inverse relationship between p53 and Ki67 
      expression (P=0.014). Moreover, p53 was significantly correlated with the OS 
      (P=0.018), but Ki67 had no significant influence on OS. CONCLUSIONS: Apatinib 
      showed promising efficiency and was well tolerated as a second-line treatment for 
      AGC patients. AGC patients with p53-negative were likely to benefit from apatinib 
      treatment; however, the expression of Ki67 proteins has no significant impact on 
      the outcome of AGC patients.
CI  - Copyright (c) 2023 Qiu, Qin, Zhang, Zhang, Zhang, Qiao, Xi, Tian and Wang.
FAU - Qiu, Zhiyuan
AU  - Qiu Z
AD  - Department of Oncology, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Qin, Rong
AU  - Qin R
AD  - Department of Oncology, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Zhang, Ziyi
AU  - Zhang Z
AD  - Department of Oncology, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Oncology, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Zhang, Zhao
AU  - Zhang Z
AD  - Department of Oncology, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Qiao, Chunyue
AU  - Qiao C
AD  - Department of Oncology, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Xi, Yan
AU  - Xi Y
AD  - Department of Geriatrics, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Tian, Guangyu
AU  - Tian G
AD  - Department of Oncology, Jiangdu People's Hospital Affiliated to Medical College 
      of Yangzhou University, Yangzhou, Jiangsu, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Oncology, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20230815
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10466417
OTO - NOTNLM
OT  - Apatinib
OT  - Ki67
OT  - gastric cancer
OT  - p53
OT  - targeted therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/01 06:43
MHDA- 2023/09/01 06:44
PMCR- 2023/01/01
CRDT- 2023/09/01 04:06
PHST- 2023/04/11 00:00 [received]
PHST- 2023/07/26 00:00 [accepted]
PHST- 2023/09/01 06:44 [medline]
PHST- 2023/09/01 06:43 [pubmed]
PHST- 2023/09/01 04:06 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1203980 [doi]
PST - epublish
SO  - Front Oncol. 2023 Aug 15;13:1203980. doi: 10.3389/fonc.2023.1203980. eCollection 
      2023.